As of 2026-03-27, the Relative Valuation of Akebia Therapeutics Inc (AKBA) is (0.27) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.39 USD, the upside of Akebia Therapeutics Inc based on Relative Valuation is -119.3%.
The range of the Relative Valuation is (0.26) - (0.28) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.8x - 16.3x | 13.6x |
| Forward P/E multiples | 12.3x - 13.9x | 13.2x |
| Fair Price | (0.26) - (0.28) | (0.27) |
| Upside | -118.4% - -120.0% | -119.3% |
| Date | P/E |
| 2026-03-23 | -70.17 |
| 2026-03-20 | -71.17 |
| 2026-03-19 | -71.17 |
| 2026-03-18 | -72.17 |
| 2026-03-17 | -74.68 |
| 2026-03-16 | -75.68 |
| 2026-03-13 | -73.17 |
| 2026-03-12 | -70.17 |
| 2026-03-11 | -70.17 |
| 2026-03-10 | -69.16 |
| 2026-03-09 | -67.66 |
| 2026-03-06 | -63.65 |
| 2026-03-05 | -59.64 |
| 2026-03-04 | -62.65 |
| 2026-03-03 | -61.14 |
| 2026-03-02 | -63.15 |
| 2026-02-27 | -65.65 |
| 2026-02-26 | -66.16 |
| 2026-02-25 | -60.64 |
| 2026-02-24 | -62.15 |
| 2026-02-23 | -60.64 |
| 2026-02-20 | -59.14 |
| 2026-02-19 | -59.14 |
| 2026-02-18 | -59.14 |
| 2026-02-17 | -60.14 |
| 2026-02-13 | -60.64 |
| 2026-02-12 | -68.16 |
| 2026-02-11 | -77.68 |
| 2026-02-10 | -75.68 |
| 2026-02-09 | -75.18 |
| 2026-02-06 | -69.66 |
| 2026-02-05 | -69.16 |
| 2026-02-04 | -68.66 |
| 2026-02-03 | -70.67 |
| 2026-02-02 | -69.16 |
| 2026-01-30 | -70.67 |
| 2026-01-29 | -72.67 |
| 2026-01-28 | -72.67 |
| 2026-01-27 | -75.68 |
| 2026-01-26 | -71.67 |
| 2026-01-23 | -68.16 |
| 2026-01-22 | -72.17 |
| 2026-01-21 | -68.66 |
| 2026-01-20 | -67.16 |
| 2026-01-16 | -68.16 |
| 2026-01-15 | -67.16 |
| 2026-01-14 | -69.16 |
| 2026-01-13 | -69.16 |
| 2026-01-12 | -70.17 |
| 2026-01-09 | -76.18 |